BELLUS Health Inc.

About BELLUS Health Inc.

BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada.

We are dedicated to bettering thelives of patients suffering from cough and particularlypatients impacted by persistent coughing.

https://www.bellushealth.com

BLU Canada

10.15USD0.25 (-2.46%)

• At close Thu Oct 06 2022

NasdaqGS exchange

Sector: Healthcare

Industry: Biotechnology

Location Canada, Laval

Grade: ACF

1,855,069,440 USD
MARKET CAP
.
PE
-0.328
BETA (5y)
-0.730
EPS

Profits

for 5 years
779%
for 3 years
24%
for 2 years
214%
for last year
64%
for this year
0%
BELLUS Health Inc.
© 2025 avazzy.com. All rights reserved
Make with 🤎 and ☕ for you!

Investing involves risk, including possible loss of principal.

The strategies discussed are strictly for illustrative and educational purposes and are not a recommendation, offer or solicitation to buy or sell any securities or to adopt any investment strategy. There is no guarantee that any strategies discussed will be effective.

International investing involves risks, including risks related to foreign currency, limited liquidity, less government regulation and the possibility of substantial volatility due to adverse political, economic or other developments. These risks often are heightened for investments in emerging/ developing markets or in concentrations of single countries.